• Return to Headlines

Relatively Low Debt-to-Capital Ratio Detected in Shares of Revance Therapeu in the Pharmaceuticals Industry (RVNC, COLL, AMPH, AGRX, AGN)

By Amy Schwartz

Below are the three companies in the Pharmaceuticals industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Revance Therapeu ranks lowest with a a Debt-to-Capital ratio of 69.1%. Collegium Pharma is next with a a Debt-to-Capital ratio of 140.1%. Amphastar Pharma ranks third lowest with a a Debt-to-Capital ratio of 1,226.5%.

Agile Therapeuti follows with a a Debt-to-Capital ratio of 2,260.2%, and Allergan Plc rounds out the bottom five with a a Debt-to-Capital ratio of 2,894.3%.

SmarTrend is tracking the current trend status for Revance Therapeu and will alert subscribers who have RVNC in their portfolio or watchlist when shares have changed trend direction.

Keywords: lowest debt-to-capital ratio revance therapeu collegium pharma amphastar pharma agile therapeuti allergan plc

Ticker(s): RVNC COLL AMPH AGRX AGN